Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Antonio Laurenza"'
Publikováno v:
Epilepsy and Behavior Case Reports, Vol 9, Iss , Pp 1-5 (2018)
Perampanel, a selective, non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, is approved for adjunctive treatment of focal seizures, with or without secondarily generalized seizures, and for primary gener
Externí odkaz:
https://doaj.org/article/43cf49322bcb41c2a4a1b69dc7f502f4
Autor:
Jaya Padmanabhan, Elena Ratti, Polyna Khudyakov, Wei Yin, Stephen Zicha, Olga Golonzhka, Tairmae Kangarloo, Brian Harel, Nancy Goodman, Emmanuelle Magueur, Craig Shering, Thor Ostenfeld, Antonio Laurenza, Arthur Simen
Publikováno v:
Tuesday, April 25.
Autor:
Wei Yin, David Han, Polyna Khudyakov, Rhett Behrje, Joel Posener, Antonio Laurenza, Dimitrios Arkilo
Publikováno v:
British journal of clinical pharmacology. 88(8)
TAK-041 (NBI-1065846), an orally available, investigational, small molecule agonist of GPR139, an orphan G-protein-coupled receptor, has shown promise in preclinical studies for the treatment of symptoms associated with schizophrenia. Here, we report
Autor:
Douglas R. Nordli, Jinping Wang, Jacqueline A. French, Emilia Bagiella, Dinesh Kumar, Antonio Laurenza, Alexis Arzimanoglou
Publikováno v:
Neurology
ObjectiveA meta-analysis of published studies was performed to determine whether the efficacy of antiseizure drugs in adults with primary generalized tonic-clonic seizures (PGTCS) is comparable with that in the pediatric population (2–12 years of a
Autor:
Jose A. Ferreira, Oneeb Majid, Ronald W. Davis, Jim Ferry, Bhaskar Rege, Sharon Dispoto, J. Ben Renfroe, Yuko Umetsu, Antonio Laurenza, Ziad Hussein, Mark Mintz
Publikováno v:
Journal of Child Neurology
Study 232, an open-label pilot study with an extension phase, evaluated the pharmacokinetics and preliminary safety/tolerability and efficacy of adjunctive perampanel oral suspension (≤0.18 mg/kg/d) in epilepsy patients aged ≥2 to
Autor:
Robert T. Wechsler, Betsy Williams, Gregory L. Krauss, Anna Patten, Manoj Malhotra, Elinor Ben-Menachem, Antonio Laurenza
Publikováno v:
Epilepsy research. 174
Although 50 % reduction in seizure frequency is a common efficacy endpoint in clinical trials of antiepileptic drugs (AEDs), 75 % or greater reductions may be required to improve patients' health-related quality of life. Identification of clinical fa
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 49(2)
Hepatic metabolism of low-clearance compound TAK-041 was studied in two different in vitro model systems using rat, dog, monkey, and human suspended cryopreserved hepatocytes and HepatoPac micropatterned coculture model primary hepatocytes. The aim o
Autor:
Betsy Williams, Robert T. Wechsler, Ivan Rektor, Antonio Laurenza, Manoj Malhotra, Gregory L. Krauss, Sunao Kaneko, Yushi Inoue, Anna Patten
Publikováno v:
Epilepsia
Objective This post hoc analysis evaluated long‐term efficacy and safety in patients with focal to bilateral tonic‐clonic seizures (FBTCS) or generalized tonic‐clonic seizures (GTCS) who entered open‐label extension (OLEx) studies to receive
Publikováno v:
Acta Neurologica Scandinavica. 137:400-408
Objectives Explore perampanel pharmacokinetics (PK) in all subjects (aged ≥12 years) vs adolescents (aged ≥12 to ≤17 years) with partial-onset seizures (POS) and identify factors explaining between-subject variability in efficacy using a popula
Autor:
Jim Ferry, Ziad Hussein, Antonio Laurenza, Oneeb Majid, Charcrin Nabangchang, Vicente Villanueva, Haichen Yang
Publikováno v:
Epilepsy Research. 127:126-134
Objective To characterize, in adolescents aged 12–17, the pharmacokinetic (PK) profile of perampanel, the impact of intrinsic and extrinsic factors on PK, and the relationships between perampanel exposure and cognitive function, seizure frequency,